ab37305 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab37305 は 8 報の論文で使用されています。

  • Tan Z  et al. HIF-1a activates hypoxia-induced BCL-9 expression in human colorectal cancer cells. Oncotarget 8:25885-25896 (2017). PubMed: 27121066
  • Xu W  et al. Hypoxia activates Wnt/ß-catenin signaling by regulating the expression of BCL9 in human hepatocellular carcinoma. Sci Rep 7:40446 (2017). PubMed: 28074862
  • Ling XH  et al. BCL9, a coactivator for Wnt/ß-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett 11:2001-2008 (2016). WB, IHC . PubMed: 26998113
  • Zhu D  et al. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med 21:572-80 (2015). IF, IHC . PubMed: 26005854
  • Zhao JJ  et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res 74:1801-13 (2014). Human . PubMed: 24599134
  • Hyeon J  et al. Prognostic Significance of BCL9 Expression in Hepatocellular Carcinoma. Korean J Pathol 47:130-6 (2013). IHC-P ; Human . PubMed: 23667372
  • Takada K  et al. Targeted disruption of the BCL9/ß-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 4:148ra117 (2012). IHC-P ; Human . PubMed: 22914623
  • Mani M  et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 69:7577-86 (2009). WB ; Human . PubMed: 19738061

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

登録